Definium Therapeutics, Inc. SEC filings DFTX
Definium Therapeutics, Inc. has 504 filings in SEC EDGAR's recent list, going back to Jun 8, 2020. Its latest annual report, Form 10-K, was filed on Feb 26, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 14, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEF 14A | Proxy statement | Apr 27, 2026 | Jun 11, 2026 |
| DEFA14A | Additional proxy material | Apr 23, 2025 | — |
| DEF 14A | Proxy statement | Apr 23, 2025 | Jun 12, 2025 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 10, 2024 |
| DEFA14A | Additional proxy material | Jun 16, 2023 | — |
| DEFA14A | Additional proxy material | Jun 15, 2023 | — |
| DEFA14A | Additional proxy material | Jun 12, 2023 | — |
| DEFA14A | Additional proxy material | Jun 9, 2023 | — |
| DEFA14A | Additional proxy material | Jun 8, 2023 | — |
| DEFA14A | Additional proxy material | Jun 8, 2023 | — |
| DEFA14A | Additional proxy material | Jun 5, 2023 | — |
| DEFA14A | Additional proxy material | Jun 5, 2023 | — |
| DEFA14A | Additional proxy material | May 31, 2023 | — |
| DEFA14A | Additional proxy material | May 31, 2023 | — |
| DEFA14A | Additional proxy material | May 25, 2023 | — |
| DEFA14A | Additional proxy material | May 25, 2023 | — |
| DEFA14A | Additional proxy material | May 25, 2023 | — |
| DEFA14A | Additional proxy material | May 24, 2023 | — |
| DEFA14A | Additional proxy material | May 22, 2023 | — |
| DEFA14A | Additional proxy material | May 18, 2023 | — |
| DEFA14A | Additional proxy material | May 12, 2023 | — |
| DEFA14A | Additional proxy material | May 12, 2023 | — |
| DEFA14A | Additional proxy material | May 12, 2023 | — |
| DEFA14A | Additional proxy material | May 9, 2023 | — |
| DEFA14A | Additional proxy material | May 4, 2023 | — |
| DEFA14A | Additional proxy material | May 2, 2023 | — |
| DEFA14A | Additional proxy material | May 2, 2023 | — |
| DEFA14A | Additional proxy material | May 2, 2023 | — |
| DEFA14A | Additional proxy material | Apr 18, 2023 | — |
| DEFA14A | Additional proxy material | May 13, 2022 | — |
| DEFA14A | Additional proxy material | Apr 18, 2022 | — |
| DEF 14A | Proxy statement | Apr 18, 2022 | Jun 1, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 8, 2022 | Jun 1, 2022 |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- DFTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1813814
- Former names
- Mind Medicine (MindMed) Inc. (until Jan 12, 2026)
Other Medicinal Chemicals & Botanical Products companies
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Source: SEC EDGAR filings. This is company-reported data, not investment advice.